Semaglutide is arguably the most popular GLP-1 compound on the market, and it is also one of the most heavily restricted topics on Facebook. If your semaglutide ads were banned, the reason is almost always related to how the platform classifies the drug.
We have helped numerous compounding pharmacies navigate semaglutide advertising on Facebook. The compound is FDA-approved under brand names like Ozempic and Wegovy, which means any mention of semaglutide triggers pharmaceutical advertising restrictions. Even compounded semaglutide is treated as a pharmaceutical product by Meta's systems.
Why Semaglutide Ads Get Banned
Facebook bans semaglutide ads because it classifies the compound as a prescription pharmaceutical. Even if your pharmacy compounds semaglutide under FDA 503A, Facebook's automated systems flag any reference to the drug name. The platform also scans for weight loss claims, which semaglutide is strongly associated with.
Common triggers include using semaglutide or Ozempic in headlines, showing weight loss before-and-after images, referencing A1C or blood sugar outcomes, and landing pages that discuss dosing or administration.
Regulatory Standards for Semaglutide Ads
FDA 503A allows compounding pharmacies to prepare semaglutide for individual patients with a prescription. Your advertising must reflect this: you offer a compounding service, not a drug product. You cannot claim compounded semaglutide is equivalent to branded versions.
FDA 503B applies if your facility compounds semaglutide at scale. Additional quality and sterility documentation is required.
DSHEA 1994 does not typically apply since semaglutide is a prescription drug, not a supplement. But the distinction matters for your compliance documentation.
The BAV appeal pathway is critical. Facebook requires verified business documentation before allowing semaglutide-related advertising.
Our Approach to Semaglutide Ads
Do not use the drug name in ads. Avoid semaglutide, Ozempic, Wegovy, and any branded terminology in headlines, descriptions, and image text. Use compounding consultation or GLP-1 therapy services instead.
Focus on the service, not the substance. Your ad should promote your compounding pharmacy's consultation services, not the drug itself. Explain that you offer compounded medications under FDA 503A guidelines.
Build a disclaimered landing page. Include clear language about FDA 503A compounding, the requirement for a prescription, and the fact that compounded drugs are not FDA-approved but prepared per individual patient needs.
Complete BAV verification. Submit all required business documentation through the Business Asset Verification process before running semaglutide-related ads.
Case Study: Semaglutide Ads Approved
A compounding pharmacy client wanted to advertise semaglutide compounding services on Facebook. Their initial ads were banned for pharmaceutical advertising policy violations. We removed all drug name references, rewrote the copy to focus on GLP-1 compounding consultations, added FDA 503A language to the landing page, and completed BAV verification. The new ads were approved within 72 hours.
Related content
Tirzepatide Ads Banned on Meta
Ready to run these ads? Book a call at calendly.com/custodio-2/30min